Tsitsi Apollo1,2, Kudakwashe C Takarinda1,3, Andrew Phillips4, Chiratidzo Ndhlovu2, Frances M Cowan5,6. 1. Department of HIV and TB, Ministry of Health and Child Care, Harare, Zimbabwe. 2. Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 3. Centre for Operations Research, International Union Against TB and Lung Disease, Paris, France. 4. Institute for Global Health, UCL, London, United Kingdom. 5. Centre for Sexual Health and HIV/AIDS Research (CeSHHAR), Harare, Zimbabwe. 6. Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Abstract
INTRODUCTION: Routine viral load (VL) testing among persons living with Human Immunodeficiency Virus (PLHIV) enables earlier detection of sub-optimal antiretroviral therapy (ART) adherence and for appropriate management of treatment failure. Since adoption of this policy by Zimbabwe in 2016, the extent of implementation is unclear. Therefore we set out to determine among PLHIV ever enrolled on ART from 2004-2017 and in ART care for ≥12 months at health facilities providing ART in Zimbabwe: numbers (proportions) with VL testing uptake, VL suppression and subsequently switched to 2nd-line ART following confirmed virologic failure. MATERIALS AND METHODS: We used retrospective data from the electronic Patient Monitoring System (ePMS) in which PLHIV on ART are registered at 525 public and 4 private health facilities. RESULTS: Among the 392,832 PLHIV in ART care for ≥12 months, 99,721 (25.4%) had an initial VL test done and results available of whom 81,932 (82%) were virally suppressed. Among those with a VL>1000 copies/mL; 6,689 (37.2%) had a follow-up VL test and 4,086 (61%) had unsuppressed VLs of whom only 1,749 (42.8%) were switched to 2nd-line ART. Lower age particularly adolescents (10-19 years) were more likely (ARR 1.34; 95%CI: 1.25-1.44) to have virologic failure. CONCLUSION: The study findings provide insights to implementation gaps including limitations in VL testing; low identification of high- risk PLHIV in care and lack of prompt utilization of test results. The use of electronic patient-level data has demonstrated its usefulness in assessing the performance of the national VL testing program. By end of 2017 implementation of VL testing was sub-optimal, and virological failure was relatively common, particularly among adolescents. Of concern is evidence of failure to act on VL test results that were received. A quality improvement initiative has been planned in response to these findings and its effect on patient management will be monitored.
INTRODUCTION: Routine viral load (VL) testing among persons living with Human Immunodeficiency Virus (PLHIV) enables earlier detection of sub-optimal antiretroviral therapy (ART) adherence and for appropriate management of treatment failure. Since adoption of this policy by Zimbabwe in 2016, the extent of implementation is unclear. Therefore we set out to determine among PLHIV ever enrolled on ART from 2004-2017 and in ART care for ≥12 months at health facilities providing ART in Zimbabwe: numbers (proportions) with VL testing uptake, VL suppression and subsequently switched to 2nd-line ART following confirmed virologic failure. MATERIALS AND METHODS: We used retrospective data from the electronic Patient Monitoring System (ePMS) in which PLHIV on ART are registered at 525 public and 4 private health facilities. RESULTS: Among the 392,832 PLHIV in ART care for ≥12 months, 99,721 (25.4%) had an initial VL test done and results available of whom 81,932 (82%) were virally suppressed. Among those with a VL>1000 copies/mL; 6,689 (37.2%) had a follow-up VL test and 4,086 (61%) had unsuppressed VLs of whom only 1,749 (42.8%) were switched to 2nd-line ART. Lower age particularly adolescents (10-19 years) were more likely (ARR 1.34; 95%CI: 1.25-1.44) to have virologic failure. CONCLUSION: The study findings provide insights to implementation gaps including limitations in VL testing; low identification of high- risk PLHIV in care and lack of prompt utilization of test results. The use of electronic patient-level data has demonstrated its usefulness in assessing the performance of the national VL testing program. By end of 2017 implementation of VL testing was sub-optimal, and virological failure was relatively common, particularly among adolescents. Of concern is evidence of failure to act on VL test results that were received. A quality improvement initiative has been planned in response to these findings and its effect on patient management will be monitored.
Authors: Shirley Lecher; Jason Williams; Peter N Fonjungo; Andrea A Kim; Dennis Ellenberger; Guoqing Zhang; Christiane Adje Toure; Simon Agolory; Georgette Appiah-Pippim; Suzanne Beard; Marie Yolande Borget; Sergio Carmona; Geoffrey Chipungu; Karidia Diallo; Marie Downer; Dianna Edgil; Holly Haberman; Mackenzie Hurlston; Steven Jadzak; Charles Kiyaga; William MacLeod; Boniface Makumb; Hellen Muttai; Christina Mwangi; Jane W Mwangi; Michael Mwasekaga; Mary Naluguza; Lucy W Ng'Ang'A; Shon Nguyen; Souleymane Sawadogo; Katrina Sleeman; Wendy Stevens; Joel Kuritsky; Shannon Hader; John Nkengasong Journal: MMWR Morb Mortal Wkly Rep Date: 2016-12-02 Impact factor: 17.586
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Kiran Jobanputra; Lucy Anne Parker; Charles Azih; Velephi Okello; Gugu Maphalala; Bernard Kershberger; Mohammed Khogali; Johnny Lujan; Annick Antierens; Roger Teck; Tom Ellman; Rose Kosgei; Tony Reid Journal: PLoS One Date: 2015-02-19 Impact factor: 3.240
Authors: Minh D Pham; Lorena Romero; Bruce Parnell; David A Anderson; Suzanne M Crowe; Stanley Luchters Journal: AIDS Res Ther Date: 2017-01-19 Impact factor: 2.250
Authors: Victor Ssempijja; Gertrude Nakigozi; Larry Chang; Ron Gray; Maria Wawer; Anthony Ndyanabo; Jingo Kasule; David Serwadda; Barbara Castelnuovo; Anja Van't Hoog; Steven James Reynolds Journal: BMC Infect Dis Date: 2017-08-22 Impact factor: 3.090
Authors: Lilian Bulage; Isaac Ssewanyana; Victoria Nankabirwa; Fred Nsubuga; Christine Kihembo; Gerald Pande; Alex R Ario; Joseph Kb Matovu; Rhoda K Wanyenze; Charles Kiyaga Journal: BMC Infect Dis Date: 2017-05-03 Impact factor: 3.090
Authors: Sarah Swannet; Tom Decroo; Sheila M T L de Castro; Caroline Rose; Ruggero Giuliani; Lucas Molfino; Ana W Torrens; Walter S E D Macueia; Sharon Perry; Tony Reid Journal: Int Health Date: 2017-07-01 Impact factor: 2.473
Authors: Trudy Tholakele Mhlanga; Richard Makurumidze; Bart K M Jacobs; Tom Decroo; Emma Govere; Hilda Bara; Prosper Chonzi; Ngwarai Sithole; Tsitsi Apollo; Wim Van Damme; Simbarashe Rusakaniko; Lutgarde Lynen Journal: AIDS Res Ther Date: 2022-07-09 Impact factor: 2.846